CHAARTED2: cabazitaxel plus abiraterone vs. abiraterone alone for metastatic CRPC

(2:7)

CHAARTED2: Improving Outcomes in Patients With mCRPC

(9:45)

Addition of cabazitaxel to abiraterone/prednisone significantly prolonged PFS in extensive disea...

(4:1econd)

Cabazitaxel Use in Metastatic Prostate Cancer

(7:9)

Cabazitaxel Improves rPFS in Patients with mCRPC

(1:22)

JEVTANA® (cabazitaxel) Mechanism of Action

(9:41)

Dr. Grivas on Potential Combinations With Cabazitaxel in Prostate Cancer

(1:4)

Cabazitaxel rechallenge in patients with metastatic castration resistant prostate cancer

(1:37)

Combination of abiraterone and cabazitaxel in metastatic castration-resistant prostate cancer

(4:6)

Cabazitaxel (Jevtana) for Progressive Metastatic Prostate Cancer after Taxotere

(3:12)

Cabazitaxel safe and effective in mCRPC

(3:47)

Dr. Sweeney on the Optimal Use of Cabazitaxel

(2:32)

CARD Trial: Cabazitaxel After AR-Targeted Therapy in mCSPC

(4:50)

A Phase II trial investigating neoadjuvant abiraterone and cabazitaxel in high-risk prostate cancer

(2:4)

Cabazitaxel Impacts Sequencing Strategies in Prostate Cancer

(1:30)

Treatment sequencing in mCRPC: cabazitaxel vs. abiraterone or enzalutamide

(1:52)

Nicholas Vogelzang, MD, explains how cabazitaxel should be used in various lines of treatment in mPC

(1:53)

Discussing the Safety Profile of Cabazitaxel in mCRPC

(34)

CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer

(4:34)

3-weekly cabazitaxel not ruled out as first-line option for metastatic breast cancer | Amit Bahl

(7:14)